Global Endobronchial Ultrasound Biopsy Market - 2023-2030

Market Overview

The global endobronchial ultrasound biopsy market reached US$ 576.7 million in 2022 and is projected to witness lucrative growth by reaching up to US$ 832.7 million by 2030. The market is growing at a CAGR of 4.8% during the forecast period (2023-2030). To diagnose peripheral pulmonary lesions, radial probe endobronchial ultrasound biopsy (RP-endobronchial ultrasound biopsy ) and guide sheath (GS)-based biopsy methods are utilized frequently.

Cryo biopsy, electromagnetic navigational bronchoscopy, and ultrathin bronchoscopy have recently been developed to aid in the precise diagnosis of lung illnesses. The mediastinal LN sampling, mediastinoscopy, is less invasive than endobronchial ultrasound biopsy -TBNA, which can also be used to sample hilar lymph nodes and can be done as an outpatient procedure with light sedation.

In the endobronchial ultrasound biopsy market, over the past few years, technology has advanced drastically, with new tools and methods being created that give more precision and quicker outcomes. Because of these developments, endobronchial ultrasound biopsy is now the method of choice for identifying lung cancer and other respiratory conditions. The ultrasound biopsy market will see high growth as it doesn't use radiation and is painless.

The endobronchial ultrasound biopsy market growth rate is high owing to various factors such as increasing demand for minimally invasive procedures because they have a number of advantages over open surgeries, such as less pain, quicker recovery, and fewer complications. Endobronchial ultrasound biopsy trend is seen as it is a less invasive technique which makes it desirable for both patients and healthcare professionals. To improve patient outcomes and lower mortality rates, lung cancer must be detected early.

Market Dynamics

The increasing prevalence of lung cancer and research and development drives the growth of the endobronchial ultrasound biopsy market.

The global market for endobronchial ultrasound biopsy is expanding as a result of the rising prevalence of lung cancer. Only 26% of lung cancer cases are identified at an early stage, despite the fact that the five-year survival rate is substantially higher (61%), according to the State of Lung Cancer 2022 Report. However, 44% of cases are discovered far too late, when just 7% of them survive. Up to 90% of occurrences of lung cancer are attributable to tobacco use, and prolonged usage is expected to increase the incidence of cancer worldwide, especially in developing countries like China, Russia, and India.

Key players are expanding their research and development efforts for technologically advanced products such as transbronchial aspiration needles. This is happening as a result of the rising demand for diagnostic tools for proper detection of lung related infections or cancer. Several firms are currently investing and putting a lot of effort in developing better ultrasound biopsy products for diagnostic purposes.

The growing investments in healthcare create lucrative growth prospects for manufacturers.

There is a sizable market opportunity for endobronchial ultrasound biopsy as it is becoming more widely accepted for the diagnosis of respiratory disorders and because the overall prevalence of lung infections is rising. Manufacturers are going to have profitable choices for growth as demand for products like transbronchial aspiration needles or biopsy forceps for diagnosis will be required.

To assist in the accurate detection of lung diseases, new technologies such as cryo biopsy, ultrathin bronchoscopy, and electromagnetic navigational bronchoscopy were just recently created. The endobronchial ultrasonography biopsy, or TBNA, which may be utilized as well for sampling hilar lymph nodes & can be performed as an outpatient operation with mild sedation, is more intrusive than mediastinoscopy, which takes place inside the mediastinum. Hence, rising investments or healthcare infrastructure spending are contributing to the growth of the market.

High cost of an endobronchial ultrasound biopsy

An endobronchial ultrasound biopsy can be expensive, and the price can change depending on the area, the medical center, and insurance coverage. In some circumstances, patients may find the expense of an endobronchial ultrasound biopsy to be exorbitant, especially in underdeveloped nations where healthcare spending is minimal.

The price of an endobronchial ultrasound biopsy procedure can be broken down into a number of different costs, including those for the tools used, the treatment itself, and any required aftercare. Depending on the health plan and the nation, insurance may occasionally pay all or part of the cost of the treatment.

COVID-19 Impact Analysis

The COVID-19 analysis includes Pre-COVID Scenario, COVID Scenario and Post-COVID Scenario along with pricing dynamics (including pricing change during and post-pandemic comparing it with pre-COVID scenarios), demand-supply spectrum (shift in demand and supply owing to trading restrictions, lockdown and subsequent issues), government initiatives (initiatives to revive market, sector or industry by government bodies) and manufacturers strategic initiatives (what manufacturers did to mitigate the COVID issues will be covered here).

Russia Ukraine Conflict Analysis

Russia started its unlawful and unprovoked full-scale invasion of Ukraine, which resulted in sanctions against Russia from the US, the UN, and other nations. In light of the current crisis, many businesses are starting to stop operating in Russia. These sanctions will surely have a significant effect on the worldwide market as businesses start to leave the Russian market. Due to worsening financial restrictions, the Russo-Ukrainian War will have a detrimental effect on the medical device industry in Russia.

Segment Analysis

The global endobronchial ultrasound biopsy market is segmented based on product type, application, End User and region.

Lung cancer diagnosis segment holds largest 63.7% of market share owing to the rising incidence of lung cancers

Lung cancer diagnosis segment will dominate the global endobronchial ultrasound biopsy market over the forecast period, owing to the rise in patients with lung cancer. Lung cancer, infections, and other disorders affecting enlarged lymph nodes in the chest can all be identified with endobronchial ultrasonography (EBUS), a minimally invasive but extremely efficient method.

EBUS enables doctors to use a method known as transbronchial needle aspiration (TBNA) to retrieve tissue or fluid samples from the lungs and adjacent lymph nodes without requiring traditional surgery. The samples can be used to identify tumours like lymphoma, diagnose and stage lung cancer, find infections, and diagnose inflammatory diseases that damage the lungs, such as sarcoidosis.

For instance, Olympus offers 19G EBUS-TBNA needles in addition to the 21G, 22G, and 25G needles, which is unmatched in the industry. The business also offers the ViziShot2 FLEX 19G, a second-generation EBUS needle that assists with histology sampling for suspected cases of lymphoma and sarcoidosis while also supplying more tissue for cutting-edge molecular analysis that enables targeted lung cancer treatment.

Geographical Analysis

North America holds 39.8% of market share owing to the strong presence of major players and increasing healthcare infrastructure investment.

Manufacturers have chances to expand their operations in this region because of the rising demand for diagnostic tools for lung infections in North America. The area has many producers and suppliers, and its rapid economic development has raised industrial production of endobronchial ultrasound biopsy, which has increased the demand.

Growth is also fueled by government measures to promote technologically advanced biopsy tools. Another issue is the rapidly expanding population with lung cancer, which has increased demand for cutting-edge, diagnostic and treatment tools. The region is growing as healthcare professionals have good knowledge about the endobronchial ultrasound biopsy tool, and they are adopting it highly for diagnosis of lung related issues among people.

Competitive Landscape

The major global players in the endobronchial ultrasound biopsy market include Olympus Corporation, CLINODEVICE, Medtronic, CONMED Corporation, Boston Scientific Corporation, Medi-Globe GmbH, Serpex Medical, MICRO-TECH (Nanjing) Co., Ltd., Cook Group Incorporated, and ACE Medical Devices Pvt. Ltd. among others.

Why Purchase the Report?

• To visualize the global endobronchial ultrasound biopsy market segmentation based on product type, application, end user and region, as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of endobronchial ultrasound biopsy market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as Excel consisting of key products of all the major players.

The global endobronchial ultrasound biopsy market report would provide approximately 53 tables, 54 figures and 195 Pages.

Target Audience 2023

• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies